Cambridge Epigenetix

Our starting point is TrueMethylTM oxidative bisulfite sequencing (oxBS-Seq), a novel technology that pioneers quantitative, single-base resolution sequencing of the modified bases hydroxymethyl cytosine (5-hmC) and methylcytosine (5-mC). TrueMethyl enables analysis of the DNA methylome with unprecdented accuracy and opens new avenues for basic research, pharmaceutical discovery and diagnostics. Recent studies have shown that at some sites in the genome the level of 5-hmC can be comparable to the level of 5-mC, emphasizing the importance of identifying these variants accurately. However, traditional bisulfite sequencing cannot discriminate between 5-hmC and 5-mC. Co-invented by Prof. Shankar Balasubramanian, who previously co-invented the Solexa / Illumina sequencing-by-synthesis platform, and Michael Booth, innovative oxBS-Seq technology utilises a selective chemical oxidation that accurately distinguishes between 5-mC and 5-hmC. TrueMethyl can be used with a variety of common platforms including next generation sequencing systems, methylation arrays, and targeted assays. Employing chemical oxidation gives very high conversion efficiencies and minimises sequence context effects, giving results of unparalleled quality. TrueMethyl enables: Quantitative measurement of 5-hmC and 5-mC in parallel Single-base resolution methylation and hydroxymethylation analysis Confirmation of the location of unmethylated cytosines CEGX is funded by Syncona Partners as well as Cambridge Enterprise and our management team comprises industry leaders and epigenetics expertise.
Type
Private
HQ
Great Shelford, GB
Founded
2012
Employees
27 (est)+8%
Cambridge Epigenetix was founded in 2012 and is headquartered in Great Shelford, GB

Key People at Cambridge Epigenetix

Jason Mellad

Jason Mellad

Business Development Manager
Mike Booth

Mike Booth

Research Scientist
Fedja Bobanovic

Fedja Bobanovic

CEO
Shankar Balasubramian

Shankar Balasubramian

Co-Founder and Director
Christine Clark

Christine Clark

R&D Scientist
Neil Bell

Neil Bell

Research Scientist

Cambridge Epigenetix Locations

Great Shelford, GB
Cambridge, CB22 3AT, GB

Cambridge Epigenetix Metrics

Cambridge Epigenetix Summary

Founding Date

2012

Total Funding

$26.5 M

Latest funding size

$21 M

Time since last funding

9 months

Investors

Cambridge Epigenetix's latest funding round of $21 M was in March 2016. In total, Cambridge Epigenetix has raised $26.5 M.
12% of current employees of Cambridge Epigenetix are female and 88% are male.

Cambridge Epigenetix News

Cambridge Epigenetix Company Life

You may also be interested in